We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
NAVA.OL

Price
26.00
Stock movement up
+0.80 (3.17%)
Company name
Navamedic ASA
Exchange
(OL
,
Currency
NOK
)
Sector
Healthcare >
Medical Distribution
Markedsværdi
623.52M
Ent værdi
849.85M
Pris/omsætning
1.19
Pris/bog
2.88
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
13.03
PEG
-
EPS-vekst
-
1 års afkast
7.04%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2025-12-15

UDBYTTE

NAVA.OL betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF8.39
Pris til FCF17.13
Pris til EBITDA11.71
EV i forhold til EBITDA15.96

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning1.19
Pris til egenkapital2.88
EV i forhold til salg1.62

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier23.98M
EPS (TTM)-
FCF pr. aktie (TTM)-

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)-
Bruttofortjeneste (TTM)-
Driftsindkomst (TTM)-
Nettoindkomst (TTM)-
EPS (TTM)-
EPS (1 år frem)2.00

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter42.66M
Nettotilgodehavender64.93M
Omsætningsaktiver i alt218.31M
Goodwill163.67M
Immaterielle aktiver89.94M
Ejendomme, anlæg og udstyr6.98M
Sum aktiver485.55M
Kreditor80.37M
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser167.59M
Sum gæld269.00M
Aktionærernes egenkapital216.55M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-
Investeringsudgifter (TTM)-
Fri pengestrøm (TTM)-
Udbetalt udbytte (TTM)-

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-
Afkast af aktiver-
Afkast af investeret kapital-
Kontant afkast af investeret kapital-

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning25.90
Daglig høj26.40
Daglig lav25.60
Daglig volumen63K
Højeste gennem alle tider41.89
1 års analytiker estimat34.00
Beta0.19
EPS (TTM)-
Udbytte pr. aktie0.00
Ex-div dato13 Apr 2010
Næste dato for resultatpræsentation12 Feb 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
NAVA.OLS&P500
Nuværende prisfald fra top notering-37.93%-1.22%
Højeste prisfald-57.39%-19.00%
Højeste efterår dato9 Apr 20258 Apr 2025
Gennemsnitlig fald fra toppen-45.46%-2.64%
Gennemsnitlig tid til nyt højdepunkt-6 days
Maks. tid til nyt højdepunkt298 days89 days
OPLYSNINGER OM VIRKSOMHEDEN
NAVA.OL (Navamedic ASA) company logo
Markedsværdi
623.52M
Markedsværdi kategori
Small-cap
Beskrivelse
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is based in Oslo, Norway.
Personale
42
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
In the third quarter 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, del...
28. oktober 2025
Product licensor Orion Corporation has also received final confirmation for the Finnish market.
14. august 2025
In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, del...
14. august 2025
Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. O...
13. august 2025
The acquired product assets from dne pharma include Ventizolve, Levopidon and Metadon Dne.
16. juli 2025
Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase ...
15. juli 2025
The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the agenda were approved in accordance with the board of directors' proposals. A copy of the minu...
14. juli 2025
Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use wi...
27. juni 2025
The acquisition marks Navamedic's entry to the field of addiction treatment.
24. juni 2025
Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") yesterday, on June 23, regarding Navamedic entering into an asset purchase agreement f...
24. juni 2025
Næste side